Complete if Known Substitute for form 1449/PTO 10/789,627-Conf. #7662 Application Number INFORMATION DISCLOSURE February 26, 2004 Filing Date STATEMENT BY APPLICANT **First Named Inventor Howard KAUFMAN** Art Unit 1632 (Use as many sheets as necessary) Anoop Kumar Singh Examiner Name Sheet 1 of 1 0019240.00461US2 Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>If known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.ssin.ass or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	A1	TOSO et al., "Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients with Metastatic Melanoma": (2002) J Clin Oncol. 20(1):142-52		
	A2	MEDINA and GUZMAN, "Use of Live Bacterial Vaccine Vectors for Antigen Delivery: Potential and Limitations" (2001) <i>Vaccine</i> 19:1573-80		
	A3	CHANG et al., "Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium" (1992) Cancer Res. 52(1): 181-6		
	A4	LEE et al., "Cdk4 and p27 <sup>Kip1</sup> play a role in PLC-g1-mediated mitogenic signaling pathway of 18 kDa FGF-2 in corneal endothelial cells" (2002) <i>Mol Vis</i> . 8:17-25		
	A5	Pawelek et al., "Bacteria as Tumour-Targeting Vectors" (2003) Lancet Oncol. 4:548-56		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Evaminor	Date	
Examiner	Date	
Signature	Considered	
6441621		

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.